Previous 10 | Next 10 |
Axovant Sciences Ltd ( AXON ) is approaching two key catalysts which may attract the attention of the markets. When I last wrote about the company , I noted that I didn't like the decisions being made at AXON. Throughout 2019 we may begin to see if the company's risky decision, to pivot into ...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Neurocrine Biosciences, Inc. (NBIX) Q4 2018 Earnings Conference Call February 5, 2019 4:30 PM ET Company Participants Kevin Gorman – Chief Executive Officer Jane Sorensen – Head-Investor Relations Matt Abernethy – Chief Financial Officer Eiry Roberts ȁ...
Neurocrine Biosciences (NASDAQ: NBIX ) Q4 results ($M): Revenue: 131.5 (+39.2%); Ingrezza sales: 130.3 (+102.0%). More news on: Neurocrine Biosciences, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ): Q4 GAAP EPS of $0.19 beats by $0.01 . More news on: Neurocrine Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended December 31, 2018 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. ...
ALL , APC , APU , ASH , ATO , BE , BRKS , CB , CERN , DATA , DIS , DLR , DOX , EA , GNW , HCLP , HIW , JKHY , MANH , MCHP , MDU , MODN , MTSI , MXL , MYGN , NANO , NBIX , OI , PAA , PAGP , PAYC , PDM , PLT , SFLY , SNAP , SU , SWKS , TCS , TENB , TMK ...
I have been pretty consistently bullish on Neurocrine ( NBIX ) for a while, but one of my more frequent criticisms has been a relatively spartan pipeline. Where some biotechs will throw numerous compounds into trials in the hopes that something “sticks”, Neurocrine has been far...
Thinly traded micro cap Voyager Therapeutics (NASDAQ: VYGR ) is up 37% premarket on light volume in reaction to its out-licensing deal with Neurocrine Biosciences (NASDAQ: NBIX ) under which the latter will own development and commercialization rights to gene therapy programs f...
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains development and commercialization rights to gene therapy programs VY-AADC for Parkinson’s...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...